State of Play

We are experiencing a “golden twenties” in science with breakthrough therapies in rare diseases, oncology, cell and gene therapy, and regenerative medicine, but…

  • Biotech and Big Pharma will bring a record number of NCEs and biologics to market

  • Precision-medicine at the core

  • Drug development model essentially unchanged since 1960ies intro of RCTs and evidence-based medicine

  • Prices for new drugs keep going up

  • Combined budget impact will put pressure on government and private payers

Opportunity to re-purpose and improve established therapies with novel drug design and delivery systems

  • Improve established therapies with novel drug design and delivery systems

  • Re-purpose known drugs based on new science; design new patentable molecules and delivery systems

Opportunity to transform drug development leveraging digital solutions

  • Established biopharma is conservative and without incentives to cut development costs

  • Many tech companies, incl start-ups, have individually novel digital solutions but fail to evolve into a decentralised ecosystem

  • Patient-centricity still not at the centre of the biopharma development model